Last reviewed · How we verify
Ra-223 in combination with enzalutamide
Ra-223 in combination with enzalutamide is a Small molecule drug developed by Taro Iguchi, MD, PHD. It is currently in Phase 2 development.
At a glance
| Generic name | Ra-223 in combination with enzalutamide |
|---|---|
| Sponsor | Taro Iguchi, MD, PHD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase III Radium 223 mCRPC-PEACE III (PHASE3)
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (PHASE3)
- Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer (PHASE3)
- Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC (PHASE3)
- Radium-223 in Combination With Enzalutamide (PHASE2)
- The Combination Therapy With Ra-223 and Enzalutamide (PHASE2)
- Multi-academic Center Study of Xofigo Patients
- A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ra-223 in combination with enzalutamide CI brief — competitive landscape report
- Ra-223 in combination with enzalutamide updates RSS · CI watch RSS
- Taro Iguchi, MD, PHD portfolio CI
Frequently asked questions about Ra-223 in combination with enzalutamide
What is Ra-223 in combination with enzalutamide?
Ra-223 in combination with enzalutamide is a Small molecule drug developed by Taro Iguchi, MD, PHD.
Who makes Ra-223 in combination with enzalutamide?
Ra-223 in combination with enzalutamide is developed by Taro Iguchi, MD, PHD (see full Taro Iguchi, MD, PHD pipeline at /company/taro-iguchi-md-phd).
What development phase is Ra-223 in combination with enzalutamide in?
Ra-223 in combination with enzalutamide is in Phase 2.